NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyAcquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia
About This Grant
We request funds to acquire a Bruker timsTOF Ultra 2 mass spectrometers for the Proteomics Core Facility at the Children’s Hospital of Philadelphia (CHOP) Research Institute. This high-end instrument will replace an aging Thermo QE HF system, which no longer meets the sensitivity, speed, or flexibility demands of modern proteomics. The Ultra 2 will dramatically expand our capacity to support NIH-funded research projects that rely on high-resolution, quantitative proteomic profiling of clinically relevant and low-input samples, many of which are not feasible with our current instrumentation. The CHOP Proteomics Core has a strong record of enabling both basic and translational research, with deep expertise in mass spectrometry method development and collaborative project support. Our team has contributed to numerous NIH-funded studies in pediatric heart disease, cancer, metabolic disorders, and infectious diseases. Following a rigorous head-to-head evaluation, the Bruker timsTOF Ultra 2 was selected for its superior sensitivity, acquisition speed, and upgradable modular design, features particularly critical for HLA peptidomics and other advanced applications. The instrument will be housed in a well-supported core facility with dedicated infrastructure and oversight by a newly established Advisory Committee to ensure equitable access and sustained scientific impact. With 15 NIH-funded investigators identified as major and minor users, and an additional 11 researchers supported by non-NIH funding or preparing NIH submissions, this acquisition will directly advance cutting-edge research and expand access to transformative proteomics technologies across the CHOP research community.
Grant Summary
Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia is a OD - NIH Office of the Director grant providing up to $1.2M for university, nonprofit, healthcare org. Applications are due 2027-05-17 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $1.2M
2027-05-17
- 1Confirm your organization is eligible for Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia from OD - NIH Office of the Director, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to OD - NIH Office of the Director before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against OD - NIH Office of the Director's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia: Frequently Asked Questions
Who is eligible for the Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia?
Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia is offered by OD - NIH Office of the Director and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia provide?
Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia provides up to $1.2M per award from OD - NIH Office of the Director. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia deadline?
Applications for Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia are due 2027-05-17 (open). Because deadlines can change, verify the date with the funder, OD - NIH Office of the Director, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia?
To apply for Acquisition of a Bruker timsTOF Ultra 2 to Advance Clinical and Translational Proteomics at Children’s Hospital of Philadelphia, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from OD - NIH Office of the Director.